Barr's agreement with DuPont to copromote five proprietary Barr products will continue with Bristol-Myers Squibb, the company says. Bristol told analysts last week, while discussing its $7.8 bil. DuPont acquisition, that it had not yet determined whether those products would be transferred with the acquisition or returned to Barr (1"The Pink Sheet" June 11, p. 3)
You may also be interested in...
Bristol-Myers Squibb will re-enter the radiopharmaceutical business via the acquisition of DuPont Pharma.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials